Beilu Pharma(SZ:300016)2025-04-22 07:24Financial Performance - The company achieved a revenue of 98,355.45 million yuan in 2024, representing a year-on-year growth of 10.42% [1] - Net profit attributable to shareholders reached 1,365.17 million yuan, a significant increase of 119.02% compared to the previous year [1] - The net profit of the parent company was 5,635.84 million yuan, up 838.39% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1,409.44 million yuan, reflecting a 120.27% increase [1] Comparison Agent Product Strategy - The company has successfully navigated challenges in the iodine contrast agent market, showing signs of recovery [3] - Sales revenue from contrast agents reached 58,804.95 million yuan, with a year-on-year growth of 9.87% [3] - The company expanded its product line with the approval of gadobutrol injection, enhancing its market competitiveness [3] Diabetes Medication Revenue - Sales revenue from diabetes medications, including glimepiride and repaglinide, amounted to 12,598.34 million yuan, marking a growth of 33.24% [5] Jinlianhua Granule Progress - Jinlianhua granule, a key product, is a unique formulation with applications in treating respiratory infections and is covered by various provincial procurement lists [6] - The product is expected to contribute positively to the company's portfolio following the acquisition of Tianyuan Pharmaceutical [6] Overseas Revenue Growth - The company reported overseas revenue of 13,216.14 million yuan, reflecting a year-on-year increase of 15.02% [7] - The expansion into international markets has been bolstered by compliance with EU GMP and ANVISA GMP certifications [7] R&D Developments - R&D investment for the year was 6,923.81 million yuan, a decrease of 43.40% compared to the previous year due to a more stable phase in R&D activities [9] - The company has made progress in various R&D projects, including approvals for new formulations and consistency evaluations [9]